Literature DB >> 22057131

Contribution of cystatin C gene polymorphisms to cerebral white matter lesions.

Shingo Mitaki1, Atsushi Nagai, Abdullah M Sheikh, Masaharu Terashima, Minoru Isomura, Toru Nabika, Shuhei Yamaguchi.   

Abstract

BACKGROUND: Vascular remodeling plays an important role in the development of arteriosclerosis and any of the resulting white matter lesions in the brain. An imbalance between cysteine proteases and the cysteine protease inhibitor cystatin C (CST3) may exacerbate vascular remodeling through degradation of extracellular matrix proteins. Therefore, we evaluated the association between functional polymorphisms in the CST3 gene and the development of cerebral white matter lesions.
METHODS: In a total of 2,676 participants, 3 CST3 genepolymorphisms were genotyped in 92 cases with severe deep white matter hyperintensity (DWMH), and 184 subjects were randomly selected age- and sex-matched controls without any signs of DWMH. The genetic effects of these polymorphisms on DWMH and plasma CST3 levels were examined. CST3 expression vectors were transfected into an astrocytoma cell line and the expression level of CST3 mRNA was analyzed by quantitative RT-PCR. Intracellular and secreted levels of CST3 in the cell culture were quantified by Western blot and ELISA, respectively.
RESULTS: A significant association was found between one CST3 gene haplotype and DWMH (p = 0.002). This haplotype was also associated with lower plasma CST3 levels (p = 0.01). An in vitro transfection study revealed that the +148A allele, which is included in the risk haplotype, significantly reduced the secretion and increased the intracellular accumulation of CST3; however, it had no effect on the mRNA expression.
CONCLUSIONS: Our study shows that polymorphisms in the CST3 gene are significantly associated with the likelihood of DWMH. Substitution of A for G at +148 of the CST3 gene decreased the extracellular availability of CST3 in vitro, which might result in the activation of protease activity.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057131     DOI: 10.1159/000331921

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

Review 1.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

2.  A case of late-onset leukoencephalopathy, calcifications, and cysts presenting with intracerebral hemorrhage resembling a neoplasm.

Authors:  Garrett P Banks; Shennan A Weiss; David Pisapia; Joshua Z Willey
Journal:  Cerebrovasc Dis       Date:  2013-04-30       Impact factor: 2.762

3.  Associations of serum cystatin C with depressive symptoms and suicidal ideation in major depressive disorder.

Authors:  Ting Sun; Qian Chen; Yan Li
Journal:  BMC Psychiatry       Date:  2021-11-17       Impact factor: 3.630

4.  Association between Serum Cystatin C levels and long-term cardiovascular outcomes and all-cause mortality in older patients with obstructive sleep apnea.

Authors:  Jian-Hua Li; Ying-Hui Gao; Xin Xue; Xiao-Feng Su; Huan-Huan Wang; Jun-Ling Lin; Li-Bo Zhao; Xiao Zou; Yan Gao; Jing-Jing Guo; Min Shi; Wei-Hao Xu; Ya-Bin Wang; Xiao-Shun Qian; Kai-Bing Chen; Li Fan; Lin Liu
Journal:  Front Physiol       Date:  2022-08-31       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.